- Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder.
Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder.
The Journal of pharmacology and experimental therapeutics (2016-12-15)
J Di Salvo, H Nagabukuro, L A Wickham, C Abbadie, J A DeMartino, A Fitzmaurice, L Gichuru, A Kulick, M J Donnelly, N Jochnowitz, A L Hurley, A Pereira, A Sanfiz, G Veronin, K Villa, J Woods, B Zamlynny, E Zycband, G M Salituro, T Frenkl, A E Weber, S D Edmondson, M Struthers
PMID27965369
ABSTRAKT
Although the physiologic role of muscarinic receptors in bladder function and the therapeutic efficacy of muscarinic antagonists for the treatment of overactive bladder are well established, the role of β